How a major pharma is pairing generative AI with RNAi research to speed design and prioritization of next-generation therapeutics.
Key Takeaways
- Collaboration is valued up to $2 billion with $30 million upfront consideration
- Inceptive is eligible for additional payments tied to preclinical, regulatory, and commercial milestones
- Partnership will use generative AI to design siRNA sequences and predict top candidates